A phase I study of trimethylcolchicinic acid (TMCA) given orally once daily for 5 days every 3rd week was performed in 19
patients with advanced malignancies. Myelosuppression and mucositis were the major toxicities observed. Serum TMCA levels
were monitored and appear to be useful in predicting toxicities. A partial response was seen in one lymphoma patient and stabilization
of disease was noted in one patient each with prostatic and ovarian cancer.
Supported in part by NIH DRR GCRC grant MOI RR-43